Brind.
Part of AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

How could AbbVie's next-gen drug ABBV-466 affect Royalty Pharma's revenue?

Possible What happens if… A possibility worth considering, not a forecast.

Royalty Pharma may benefit from the success of AbbVie's new immunology drug If ABBV-466 proves to be a strong successor to Skyrizi, it could significantly boost AbbVie's sales in the immunology market. Royalty Pharma holds ongoing royalty rights to AbbVie's products, meaning that increased sales of ABBV-466 would translate directly into higher royalty payments for Royalty Pharma. The drug, which combines risankizumab with trosunilimab, showed encouraging Phase 2a results, achieving higher rates of remission among patients with Crohn's disease than Skyrizi and trosunilimab monotherapy. However, the drug still needs to confirm these results in Phase 3 studies before approval can be sought.

Reported by 1 independent outlet Written Friday
Effect
Mild positive
How direct
Brind's reasoning
When
Over the long term
The story
No new developments lately

How it reaches Royalty Pharma

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • Skyrizi generated almost $10 billion in sales in the first half of the year, up 27% year over year.fool.com
  • Skyrizi's web of patents may begin to expire in the U.S. by 2033.fool.com
  • ABBV-466 achieved higher rates of remission among patients with Crohn's disease than Skyrizi and trosunilimab monotherapy in Phase 2a.fool.com
  • Royalty Pharma holds ongoing royalty rights to AbbVie's products, generating revenue from AbbVie's sales.fool.com

Why it matters

For Royalty Pharma, the success of ABBV-466 represents a potential long-term revenue uplift. Since the company's financial health is structurally defined by the lifecycle of AbbVie's products, any successful pipeline replacement for Skyrizi—AbbVie's single biggest growth driver—is critical to maintaining or growing royalty income.

This development is part of a broader industry trend where major pharmaceutical companies, like AbbVie, must constantly develop next-generation drugs to avoid catastrophic sales declines when key patents expire. AbbVie is actively seeking to challenge large competitors, such as the Dupixent empire, through assets like zumilokibart, demonstrating a strategic focus on pipeline growth.

What we don't know yet

  • What are the results of ABBV-466's Phase 3 studies?
  • How will the market react to ABBV-466's potential efficacy compared to existing treatments?

What would change this answer

ABBV-466 successfully completes Phase 3 studies and receives approvalThis would confirm its status as a strong successor to Skyrizi, leading to a more certain and potentially stronger increase in AbbVie's sales and subsequent royalty payments.
The drug fails to show significant advantage over Skyrizi or trosunilimab in Phase 3The potential for ABBV-466 to replace Skyrizi would diminish, reducing the long-term revenue upside for Royalty Pharma.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventAbbVie advances next-gen drug development to replace Skyrizi Everything aboutRoyalty Pharma

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.